Regenerative and aesthetics medicine company CollPlant Biotechnologies has secured a US patent for its photocurable dermal filler product candidate that is being developed for the aesthetics market.
Issued by the US Patent and Trademark Office, the patent is for a technique for filling the space beneath the epidermis with a polymerisable filler solution into the tissue space by the application of external light to induce in-situ polymerisation.
It is related to the company’s photocuring technology and forms the foundation of its ongoing development of photocurable dermal filler products.
The polymerisable solution was developed for injection into the tissue space and includes a modified version of recombinant human collagen (rhCollagen) and other constituents, such as hyaluronic acid.
CollPlant expects the use of photocuring technology to ease the injection process, specifically in subcutaneous and supraperiosteal applications.
CollPlant CEO Yehiel Tal said: “This patent represents an integral part of the company's strategy to expand the uses for its novel rhCollagen technology into new, high-value markets. The US is one of CollPlant's strategic target markets and we see the strengthening of our intellectual property in this territory as a significant achievement.
“In addition to its superior skin lifting capacity, the photocurable filler is designed to enable tissue regeneration and tissue contouring ability. This issued patent expiring in 2039 provides coverage for a regenerative photocurable dermal filler with contouring capabilities and we believe this will strengthen our position in the market for many years to come.”
In April 2023, CollPlant and Stratasys teamed up to jointly develop and commercialise a solution for the industrial-scale bioprinting of tissues and organs.
